CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors

Sponsor
Dana-Farber Cancer Institute (Other)
Overall Status
Completed
CT.gov ID
NCT02756390
Collaborator
National Cancer Institute (NCI) (NIH)
56
1
2
29.4
1.9

Study Details

Study Description

Brief Summary

This research study is evaluating the effectiveness of a 3-session behavioral intervention for insomnia in cancer survivors. This is a behavioral intervention study, and no medications are involved.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: CBTI-CS
  • Behavioral: Sleep Hygiene
  • Behavioral: CBTI-CS via Telehealth
N/A

Detailed Description

This study is being done to test the usefulness of a 3-session cognitive-behavioral intervention for improving insomnia in cancer survivors. In this study, the investigators are testing whether this 3-session intervention (Cognitive Behavior Therapy for Insomnia in Cancer Survivors: CBTI-CS) will improve insomnia in cancer survivors whose continue to have insomnia symptoms after receiving sleep hygiene education.

In addition to the participants who will be offered sleep hygiene education and the 3-session CBTI-CS,10 additional participants will be recruited to participate in a pilot evaluation of the CBTI-CS intervention delivered via telehealth. This will be a pilot aspect of the study and data from these participants will be for descriptive purposes.

Study Design

Study Type:
Interventional
Actual Enrollment :
56 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors
Study Start Date :
Dec 1, 2015
Actual Primary Completion Date :
May 14, 2018
Actual Study Completion Date :
May 14, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm A (Sleep Hygiene & CBTI-CS)

Participants receive a single educational session describing principles of Sleep Hygiene for Cancer Survivors. Those who continue to have significant symptoms of insomnia then receive 3 groups CBTI-CS sessions

Behavioral: CBTI-CS
CBTI-CS is a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia. Cognitive factors are addressed via cognitive restructuring and psychoeducation. Behavioral factors are addressed by structured sleep restriction, stimulus control and sleep hygiene techniques. Cancer treatment late-effects affecting sleep are addressed as potential contributors to these cognitive and behavioral factors, and as symptoms that may benefit from referral for medical evaluation/management. Participants are instructed in these cognitive-behavioral strategies as a group, but using analysis of personal sleep-log data, symptom self-reports and targeted workbook exercises, they are helped to tailor the intervention to address their specific needs.
Other Names:
  • Cognitive Behavioral Therapy for Insomnia -Cancer Survivors
  • Behavioral: Sleep Hygiene
    Education on health behaviors, sleep habits and environmental practices intended to promote good quality sleep. Recommendations target exercise and natural light exposure,use of stimulants and alcohol, daytime napping, timing of meals, creating a comfortable non-stimulating sleep space, and creating sleep rituals.

    Other: Arm B (Telehealth Pilot of CBTI-CS)

    Descriptive data collected on 10 participants (non-randomized) receiving CBTI-CS via Telehealth.

    Behavioral: CBTI-CS via Telehealth
    The CBTI-CS intervention, a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia, will be administered via live video. conferencing. Participants will have a single in-person training session and subsequent CBTI-CS group sessions will be conducted by live video conference.

    Outcome Measures

    Primary Outcome Measures

    1. The Insomnia Severity Index (ISI) [Change from Baseline to 4-weeks post-intervention]

      The ISI is a 7-item self-report questionnaire assessing severity, and impact of insomnia symptoms.

    Secondary Outcome Measures

    1. Profile of Mood States - Short Form (POMS-SF) [Change from Baseline to 4 & 8 weeks post-intervention]

      A 35-item measure which assesses mood states along several dimensions including Total Mood Disturbance.

    2. The Insomnia Severity Index (ISI) [Change from Baseline to 8 weeks post-intervention]

      The ISI is a 7-item self-report questionnaire assessing severity, and impact of insomnia symptoms.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    -≥ 18 years of age

    • History of a cancer diagnosis

    • No active cancer therapy (excluding chemoprevention) in the past year, and no cancer therapy planned in the next 6 months

    • No surgery planned in the next 6 months

    • Significant insomnia as evidenced by an Insomnia Severity Index score ≥12

    • Able to read and write in English

    • Willing to attend study group sessions

    • Motivated and able to follow the demands of the CBTI-CS program, to keep sleep records, complete self-report symptom reports and make changes in their sleep schedule, including restricting their sleep.

    Exclusion Criteria:
    • Survivors who report ever being diagnosed with Bipolar Disorder will be excluded.

    • Survivors who report ever being diagnosed with a Seizure Disorder or have experienced a seizure in the past 12 months will be excluded.

    • Intention to adjust (decrease or increase) use of sedative, hypnotic, or over-the-counter medications that can affect sleep during the study period.

    • Have diagnosed, untreated sleep apnea, or sleep apnea suspected by a physician but which has not been evaluated, or other sleep disorder

    • Employment that involves irregular sleep patterns, such as shift-work or frequent long-distance travel that involves adjusting to different time zones, or employment in a position that could impact public safety (such as operating heavy machinery)

    • Refusal to modify or reduce excessive alcohol use that is likely to interfere with an individual's sleep.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dana Farber Cancer Institute Boston Massachusetts United States 02115

    Sponsors and Collaborators

    • Dana-Farber Cancer Institute
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Christopher Recklitis, PhD, MPH, Dana-Farber Cancer Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Christopher Recklitis, Ph.D, Christopher Recklitis, PhD, MPH, Dana-Farber Cancer Institute
    ClinicalTrials.gov Identifier:
    NCT02756390
    Other Study ID Numbers:
    • 15-336
    • R03CA201459-01
    First Posted:
    Apr 29, 2016
    Last Update Posted:
    Dec 11, 2018
    Last Verified:
    Dec 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Christopher Recklitis, Ph.D, Christopher Recklitis, PhD, MPH, Dana-Farber Cancer Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 11, 2018